Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Each Mounjaro KwikPen delivers four fixed doses of 0.6 mL and will available in the Indian market in six dose strengths of  2 ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

MHRA says users of jabs such as Wegovy and Mounjaro reported inflamed pancreas - which can cause agonising abdominal pain - ...

Mounjaro has now become available on the NHS for patients in the UK, meaning doctors will have a lot more work on their ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Three months since Suzanne Harrington was prescribed the weight-loss jab Mounjaro, she opens up her diary and reveals all ...

The UK is investigating a rise in acute pancreatitis cases linked to GLP-1 weight-loss drugs, exploring possible genetic ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...